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Key Points
Both levetiracetam and phenytoin were effective in controlling seizure activity for established
status epilepticus
Levetiracetam was not significantly superior to phenytoin in seizure cessation.
Levetiracetam was not superior to phenytoin in mortality, serious adverse events, or other
adverse events.
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Abstract:
Objectives: To compare the efficacy and safety of levetiracetam and phenytoin for the
treatment of established status epilepticus
Methods

In this systematic review, we searched Medline, Embase, and Cochrane databases

from their inception with no language restrictions until May 8, 2019, for randomized controlled
trials comparing the efficacy and safety of levetiracetam and phenytoin for the treatment of
established status epilepticus. A meta-analysis was conducted to calculate the risk ratio (RR)
using random-effects models.
Results:

We identified six trials with a total of 765 participants. Levetiracetam was not

associated with an increased rate of clinical seizure cessation within 15 min compared with
phenytoin (RR, 1.03; 95%CI, 0.92-1.16; I2=23%; levetiracetam, 65.1 % [241/370] vs phenytoin,
64.3 % [222/345];19 more events [95% CI, -51 to 103] per 1000 participants; moderate-quality
evidence). The sample size met the optimum size in trial sequential analysis. There were also
no statistically significant effects on all-cause mortality (RR, 0.88; 95% CI, 0.40-1.97; I2=0%),
serious adverse events (RR, 0.51; 95% CI, 0.19-1.36; I2=0%), or any adverse events (RR, 0.95;
95% CI, 0.67-1.34; I2=0%).
Conclusions: Medium-quality evidence suggested that levetiracetam was not significantly
superior to phenytoin in seizure cessation in patients with established status epilepticus.

KEYWORDS
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1 Introduction
Convulsive status epilepticus is the second most common neurologic emergency, with an annual
incidence of 10–40 cases per 100,000 people.[1, 2] Morbidity and mortality are considerable,
and thus, timely termination of convulsive status epilepticus is the primary goal of
management.[3-5] Benzodiazepines, typically lorazepam or diazepam, are used as first-line
therapy for status epilepticus.[6-8] However, benzodiazepines fail to terminate convulsive
status epilepticus in about 40–60% of patients. The neurocritical care society guideline
recommend phenytoin, levetiracetam, or valproate for the treatment of benzodiazepinerefractory status epilepticus, also known as established status epilepticus. [Brophy et al 2012]
Yet, only fosphenytoin (a precursor drug to phenytoin) is approved by the Food and Drug
Administration (FDA) for this indication in adults, with no second-line treatments approved for
children. [6-8] Further, evidence for this indication is sparse. Most evidence for phenytoin came
from RCTs where phenytoin was administered as a second-line drug irrespective of whether
status epilepticus was controlled by benzodiazepines; the studies did not demonstrate
benzodiazepine-refractory status epilepticus.
Levetiracetam, a newer anticonvulsant, has been viewed as a potential alternative to phenytoin
for the treatment of established status epilepticus.[2] Levetiracetam can be given more rapidly
by intravenous infusion (5 min) than phenytoin (20 min).[10] In observational studies,
levetiracetam was superior to phenytoin in higher seizure cessation rates [11] and less serious
adverse events[12] for the treatment of established status epilepticus. However, data from
randomized controlled trials conducted so far does not support the use of one drug over
another.[13, 32, 33] A systematic review and meta-analysis of two small trials did not find a
statistically significant difference between levetiracetam and phenytoin, likely due to the
limited sample size.[14]
5

Since the publication of that review, several trials[15-18] on this topic have become available,
resulting in a combined sample size that is 5 times greater than the previous meta-analysis.
Therefore, we performed a systematic review and meta-analysis to compare the efficacy and
safety of levetiracetam versus phenytoin as the treatment of established status epilepticus. We
also performed trial sequential analyses to identify if firm evidence is reached in cumulative
studies.

2 MATERIALS AND METHODS
2.1 Protocol and guidance
This study protocol and hypotheses is registered on the Open Science Framework
(https://osf.io/b3zjn). The systematic review was conducted following the recommendations of
The Cochrane Handbook for Systematic Reviews of Interventions[19] and the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.[20] The
PRISMA checklist is presented in Supplement eTable 1. Ethical approval was not obtained
because this is a systematic review.

2.2 Eligibility criteria
Inclusion criteria following PICOS (population, interventions, comparators, outcomes, and
study design):
(1) Population: The population of interest included patients with convulsive status epilepticus
6

(generalized or focal) despite first-line antiepileptic drugs (e.g., benzodiazepines) . Status
epilepticus was defined as convulsive seizures lasting >5 minutes
(2) Intervention: Intravenous levetiracetam.
(3) Comparison: Intravenous phenytoin (fosphenytoin in the USA)
(4) Outcome: The primary outcome was clinical seizure cessation within 15 min. Secondary
outcomes were all-cause mortality, admission to critical care, and good functional outcome.
(5) Study design: Randomized controlled trials
Exclusion Criteria: Types of myoclonic, absence, or non-convulsive status epilepticus.

2.3 Data Sources
We searched the databases Medline (from 1956 to May 8, 2019), Embase (from 1976 to May
8, 2019), and Cochrane databases (from 1992 to May 8, 2019) . We also checked the reference
lists of previous reviews for additional studies. We searched trial registries on ClinicalTrials.gov
for ongoing studies or the availability of completed studies. We did not use any language
restrictions. Details of the search strategy used for each database are reported in Supplement
eTable 2.

2.4 Study selection
After removal of duplicates, two authors (YZ and LJ) independently screened the title and
abstracts of the search results. The full text of the remaining papers was assessed independently
by the two authors. Disagreements between the two authors were resolved by a third reviewer
7

(FF).

2.5 Data collection process
Two authors (YZ and YF) independently extracted data on study characteristics and event rates
from the eligible trials into standardized collection forms. The following baseline
characteristics were extracted from the included studies: key study characteristics (e.g., first
author, year of publication, study design, country in which the study was performed and number
of cite, study period, number of included patients, sex, age, initial dosages) and quantitative
outcomes (clinical seizure cessation, all-cause mortality, admission to critical care). The data
was collected on an intention-to-treat principle. Disagreements between the two authors were
resolved by a third reviewer (FF).

2.6 Risk of Bias, Publication Bias, and Quality of Evidence
Two authors (FF and LL) independently assessed the risk of bias with the Cochrane
Collaboration risk of bias tool across five domains (sequence generation, allocation
concealment, blinding, detection bias, and attrition bias).[21] Each domain was assessed as
either low, unclear, or high risk of bias. Disagreements between the two authors were resolved
by a third reviewer (FF). Two authors (YZ and YF) independently rated the confidence in the
estimates of effect for each outcome using the Grading of Recommendations, Assessment,
Development and Evaluation (GRADE).[22] We assessed the small-study effect using a visual
estimate of the funnel plot and Egger’s test, Begg’s test, and Harbord’s test when 10 or more
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trials were pooled.[23]

2.7 Data synthesis
All statistical analyses were performed using RevMan (5.3.3; The Cochrane Collaboration).
Pooled effect sizes were calculated using a random-effects model. For dichotomous outcomes,
we calculated risk ratios (RR) and 95% CIs with the Mantel–Haenszel method. Statistical
significance testing was 2-sided and P<.05 was considered statistically significant.
Heterogeneity was assessed using the Chi2 test and the I2 test, with I2 > 50% considered
substantial.[24]

2.8 Trial sequential analysis
We conducted trial sequential analysis[25] for the primary outcome to explore whether
cumulative data were adequately powered to evaluate outcomes. Trial sequential analysis was
used to maintain an overall 5% risk of type I error, an anticipated relative risk reduction of
20.0%, and a control event rate of 67.0%. TSA viewer version 0.9.5.10 Beta (Copenhagen Trial
Unit, Centre for Clinical Intervention Research, Copenhagen, DE. 2016) was used for analysis.

2.9 Subgroup analysis
Because of the concern that the effect of levetiracetam may differ in children and adults, we
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stratified trials by age into two categories: children (age<18 years old) vs adults (age>18
years old).

2.10 Sensitivity analyses
Sensitivity analyses were done to explore potential heterogeneity by (1) excluding trials at each
time, (2) using fixed-effect models, (3) excluding trials with a high risk of bias, (4) excluding
trials with less than 100 patients.

3 Results
3.1 Study selection and study characteristics
Details of the study selection process are presented in Figure 1. We identified 965 studies in the
systematic electronic literature search, and we also identified two additional trials after
checking previous reviews. After removal of records according to pre-specified criteria, 13 fulltext reports were reviewed for potential eligibility. After exclusion of incomplete reports[14,
26-31], six trials[15-18, 32, 33] were deemed eligible and included in the meta-analysis. The
reasons for excluding trials that underwent full-text review are presented in Supplemental
eTable 3.
The key characteristics of all included studies are summarized in Table 1 and eTable 4-5. Across
the six trials, 765 participants were enrolled (390 randomized to levetiracetam, 375 randomized
to phenytoin). The number of participants ranged from 44 to 286. The trials were published
10

between 2015 and 2019. Two trials[17, 18] were multicenter, and four[15, 16, 32, 33] were
single-center.

3.2 Risk of Bias and Quality of Evidence
Risk-of-bias assessments are reported in Supplement eFigure 1 and 2. Three trials[15, 17, 18]
were deemed at high risk of bias because of the unblinded design; one trial[32] was high risk
for selection bias. Two trials[16, 33] were ranked as unclear risk. Key findings of GRADE
assessment for main outcomes are shown in Supplement eTable 6.

3.3 Primary outcome
Of the six trials included in the meta-analysis, five trials were included in primary outcome
assessement as they provided information on clinical seizure cessation within 15 min. The rates
of seizure cessation within 15 min were 65.1 % (241/370) in the levetiracetam group and 64.3 %
(222/345) in the phenytoin group. Compared with phenytoin, levetiracetam was not associated
with a high rate of clinical seizure cessation (RR, 1.03; 95%CI, 0.92-1.16; I2=23%; moderatequality evidence; Figure 2). We did not perform analysis to detect small-study effects due to the
low number of trials. The planned subgroup analysis of adult and pediatric patients was not
performed, because there were no trials that only included adults (age > 18 years). Sensitivity
analyses showed similar results in clinical seizure cessation for all of the following: excluding
trials one at a time, using fixed-effect models, excluding trials with a high risk of bias, excluding
trials with less than 100 patients (Supplement eTable 7). In trial sequential analyses of clinical
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seizure cessation, the effect estimate lay outside the futility boundary for relative risks of 20%,
meaning there is reliable evidence that overall, levetiracetam compared with phenytoin does
not increase the rate of clinical seizure cessation by 20% (Supplement eFigure 3). However, in
the pediatric subgroup, trial sequential analyses showed that the optimum size was not met
(Supplement eFigure 4).

3.4 Secondary outcomes
The forest plots of secondary outcomes are shown in Figure 3. Similar with primary outcome,
levetiracetam was not superior to phenytoin in good functional outcome (RR, 1.05; 95% CI,
0.90-1.23; I2=0%), admission to critical care (RR, 1.15; 95% CI, 0.97-1.36; I2=0%), or all-cause
mortality (RR, 0.88; 95% CI, 0.40-1.97; I2=0%).

4 Discussion
In this meta-analysis of 6 trials with a total of 765 patients, we did not detect a significant
difference between phenytoin and levetiracetam for the treatment of established status
epilepticus with regards to any outcome, including clinical seizure cessation within 15 minutes
and safety. Both drugs were effective in controlling seizure activity after the failure of first-line
treatment(benzodiazepines). These findings were not changed after sensitivity analyses were
performed.
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4.1 Comparison with other studies
A previous review with a similar analysis approach showed the absence of a statistically
significant difference because of the lack of statistical power to detect a difference.[14] The
previous review only included two small trials with a total of 157 adults. Hence there was
considerable uncertainty around the conclusions and children could not be examined. Our
findings are consistent with the previous review. However, our study differed in the following
four aspects. First, our comparative analysis was the largest to date, comprising data, five times
larger than the previous study, which has made it possible to improve the precision of the
outcomes. Second, trial sequential analysis showed that our data meet the minimum information
size, which increased the reliability of the results. Third, we have also provided absolute as well
as relative risks and a formal rating of the quality of the evidence and documented the credibility
of the primary outcome. Fourth, we quantified several new findings, including no difference
between both groups in all-cause mortality, serious adverse events, non-serious adverse events,
and admission to critical care.
After this study was submitted for initial review, an additional trial, the Established Status
Epilepticus Treatment Trial (ESETT), was published.[13] The ESETT trial compared the
efficacy and safety of levetiracetam, fosphenytoin, and valproate in children and adults with
established status epilepticus, and found the three drugs were associated with similar incidences
of seizure cessation. Though our results were similar to that of the ESETT trial, our study
quality was inferior to the ESETT trial, which is a high-quality, double-blind, multi-site
randomized trial that was well-powered to detect a difference between levitiracetam,
fosphenytoin and valproate.

4.2 Strengths and limitations
13

We conducted this study based on an a priori protocol that defined a rigorous methodological
approach based on the Cochrane Handbook. We also assessed the quality of evidence using
GRADE (and found the quality for many critical outcomes moderate) and the minimum
information size using in the trial sequential analysis in the overall analysis (and found our data
meet the minimum information size).
This study had limitations. First, the main limitation of this study was the overall moderate
methodological quality of included trials. The two large trials were delivered without blinding.
Second, the number of included trials was limited, and thus we were unable to evaluate the bias
resulting from small-study effects (i.e. smaller studies show greater treatment effects than larger
ones). However, the potential bias may be low because all included trials had negative results.
Third, although there were no significant difference between rates of adverse events in
levetiracetam and phenytoin, levetiracetam showed a trend in reduced risk of serious adverse
events. Also, caution is required when interpreting adverse events due to the extremely wide
confidence intervals.
Fourth, trials included in this systematic review differed in their definition of convulsive status
epilepticus, including the time of prolonged seizures and types of status epilepticus (generalized
convulsive SE / focal motor SE). It may be a possible source of clinical heterogeneity.
Fifth, we used trial sequential analyses to control the risks of type I and type II errors. However,
the use of trial sequential analyses has been criticized, and it appears more controversial to
ignore the risks of random errors.[34] Interpretation of trial sequential analyses is complex and
should be considered with caution.
Finally, while our meta-analysis specified the second-line treatment, it did not specify
14

demonstrated refractoriness to the first-line benzodiazepine treatment. Four of six trials
described in their methods section how patients who failed the first-line benzodiazepine was
enrolled and patients who responded to benzodiazepine was excluded. However, two trials
allocated second-line treatments immediately after benzodiazepine administration.[15,33] The
two trials did not provide time for observing the cessation of epileptic activity, and some of the
patients may have seizure cessation not attributable to the second-line treatment, leading to
clinical heterogeneity in our meta-analysis.

4.3 Implications
In the past decade, guidelines recommend phenytoin as the treatment of established status
epilepticus after the failure of first-line treatment with benzodiazepines.[6-8] The use of
alternative drugs had been limited by the lack of high-quality evidence for this indication.
Results of our meta-analysis of randomized trials suggests that levetiracetam and phenytoin had
similar efficacy and safety for the treatment of established status epilepticus. Another recently
published head-to-head trial provided stronger evidence for the same conclusion. In light of the
evidence, recommendations for second-line treatment could be expanded.
Nonetheless, our findings should be interpreted with caution because a planned subgroup
analysis stratified by age was not performed. The subgroup analysis was not conducted was due
to a lack of trials that enrolled only adults, and the sample size of trials conducted in children
failed to meet the optimum size in trial sequential analysis.

5 Conclusions
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This meta-analysis did not find evidence supporting that levetiracetam was superior to
phenytoin in cessation rate of clinical seizure within 15 minutes.
We confirm that we have read the Journal’s position on issues involved in ethical publication and
affirm that this report is consistent with those guidelines
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Figure descriptions:
Figure 1 Search strategy and final included and excluded studies
Figure 2 Association of levetiracetam versus phenytoin with clinical seizure cessation.
Figure 3 ssociation of levetiracetam versus phenytoin with all-cause mortality, admission to
critical care, and good functional outcome
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Table 1 Characteristics of trials included
Trials

Country

Site

Age

Patients, N

Mean age

Female, %

range

LEV

PHT

LEV

PHT

LEV

PHT

Initial Dosages
LEV

PHT

Mundlamuri 2015

India

1

> 15

50

50

34.78±13.64

33.24±13.39

36

44

25 mg/kg

20 mg/kg at 50 mg/min

Chakravarthi 2015

India

1

> 14

22

22

39.00±18.40

31.82±12.68

45

32

20 mg/kg at 100 mg/min

20 mg/kg at 50 mg/min

Gujjar 2017

Oman

1

> 15

22

30

38±19

37±19

41

30

30 mg/kg over 30 min

20 mg/kg over 30 min

Senthilkumar 2018

India

1

0.25-12

25

25

2.28±2.19

3.34±3.36

28

36

30mg/kg over 7 min

20mg/kg

Dalziel 2019

Australia, New Zealand

13

0.25-16

119

114

3.8±3.8

4.0±3.9

50

54

20mg/kg over 5 min

20 mg/kg over 20 min

Lyttle 2019

UK

30

0.5-18

152

134

2.7

2.7

51

46

40 mg/kg over 5 min

20 mg/kg (max 2g)
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